Algerian state-owned pharmaceutical company Saidal is currently engaged in negotiations with multiple suppliers from various countries, including India, to secure the raw materials needed for the production of chloroquine. This medication has shown efficacy in treating COVID-19 patients. According to Saidal's CEO, Fatouma Akacem, the company possesses the necessary equipment and expertise to manufacture up to 1 million units of hydroxychloroquine.
Saidal's production capacity for chloroquine could potentially reach 5 million units in the near future, provided that the company can secure a stable supply of raw materials. Chloroquine is primarily used to treat and prevent malaria, as well as certain rheumatological and dermatological conditions. Its effectiveness in treating COVID-19 patients has led to increased demand for the medication.
In addition to chloroquine production, Saidal has also started manufacturing hydro-alcoholic gel, a product in high demand due to the COVID-19 pandemic. The company's Constantine unit has produced and distributed 20,000 flacons of 1-liter gel, which were provided free of charge to the Pharmacie centrale des hôpitaux and public institutions.
Saidal's CEO, Fatouma Akacem, announced that the company will expand its production of hydro-alcoholic gel to include smaller formats of 100 ml and 200 ml in the second phase. Furthermore, Saidal has made available a range of products, including paracetamol and various vitamins such as C, zinc, and magnesium, to cater to the needs of the population during the pandemic.
According to Akacem, a substantial quantity of these products is available at Saidal's production centers. The company's efforts aim to address the increased demand for essential medications and products amid the COVID-19 pandemic. Saidal's production and distribution of these products are expected to help alleviate some of the pressure on Algeria's healthcare system.
The company's proactive approach to securing raw materials and ramping up production is seen as a positive step in supporting Algeria's response to the pandemic. Saidal's ability to manufacture essential medications and products domestically can help reduce reliance on imports and ensure a more stable supply chain.
As the situation with COVID-19 continues to evolve, Saidal's efforts to increase production of chloroquine and other essential products will likely play a critical role in supporting public health efforts in Algeria. The company's progress in securing raw materials and expanding production will be closely watched in the coming weeks and months.
Key points
- Saidal in negotiations with suppliers to secure raw materials for chloroquine production.
- Company's production capacity for chloroquine could reach 5 million units.
- Saidal expands product line to include hydro-alcoholic gel and other essential medications.
